07/12 Settlement Notice – Stemline Therapeutics, Inc.
To: All persons and/or entities who purchased common stock in Stemline Therapeutics, Inc. (NASDAQ: STML). during the period from January 19, 2017 through February 1, 2017, and were damaged thereby; a settlement has been announced in the securities litigation known as In re Stemline Therapeutics, Inc. Securities Litigation, Master File No. 1:17-CV-00832-PAC, United States District Court for the Southern District of New York. For additional information about this settlement, please see the Notice and Proof of Claim (links provided below): Notice of Pendency and Proposed Settlement of Class Action and Settlement Fairness Hearing; Proof of Claim and Release. Claim submission […]